Tejara Capital’s Cardiol Therapeutics CRDL Stock Holding History

Tejara Capital’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.93M	Hold	5,130,122	–	–	2.28%	12
2025 Q4	$4.89M	Buy	5,130,122 +2,500,000	+95%	+$2.62M	1.15%	18
2025 Q3	$2.81M	Sell	2,630,122 -635,697	-19%	-$771K	1.47%	25
2025 Q2	$4.44M	Buy	3,265,819 +70,829	+2%	+$82.5K	2.06%	14
2025 Q1	$3.1M	Buy	3,194,990 +79,553	+3%	+$97.7K	1.2%	24
2024 Q4	$3.99M	Buy	3,115,437 +1,344,167	+76%	+$2.27M	2.61%	14
2024 Q3	$3.51M	Buy	1,771,270 +49,027	+3%	+$102K	1.67%	21
2024 Q2	$3.48M	Buy	1,722,243 +77,833	+5%	+$165K	1.26%	29
2024 Q1	$2.98M	Buy	1,644,410 +527,734	+47%	+$711K	1.09%	29
2023 Q4	$942K	Buy	1,116,676 +471,219	+73%	+$400K	0.39%	47
2023 Q3	$578K	Buy	645,457 +148,396	+30%	+$142K	0.33%	51
2023 Q2	$442K	Buy	497,061 +56,435	+13%	+$37.3K	0.22%	59
2023 Q1	$215K	Hold	440,626	–	–	0.11%	76
2022 Q4	$225K	Buy	+440,626	New	+$269K	0.13%	85

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tejara Capital's CRDL Position: Q1 2026 in Review

Tejara Capital held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 5,130,122 shares worth $6.93M. The position accounts for 2.28% of the portfolio, ranked #12.

Tejara Capital first reported a position in CRDL in Q4 2022 and has held it in 14 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

Tejara Capital held 5,130,122 shares of Cardiol Therapeutics worth $6.93M as of Q1 2026.
Tejara Capital left its Cardiol Therapeutics share count unchanged in Q1 2026.
Cardiol Therapeutics made up 2.28% of Tejara Capital's portfolio in Q1 2026, its #12 holding.
Tejara Capital first reported a position in Cardiol Therapeutics in Q4 2022 and has held it in 14 quarters since.
47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Tejara Capital's 13F filing for Q1 2026, filed 12 May 2026.